Afya Limited (NASDAQ:AFYA – Get Free Report) has earned an average rating of “Hold” from the seven research firms that are currently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $17.25.
Several research analysts have commented on the stock. Bradesco Corretora raised shares of Afya to an “outperform” rating and set a $17.00 price objective for the company in a report on Thursday, September 24th. Zacks Research upgraded Afya from a “strong sell” rating to a “hold” rating in a research note on Monday, October 5th. JPMorgan Chase & Co. raised shares of Afya from a “neutral” rating to an “overweight” rating and lowered their target price for the stock from $21.00 to $19.00 in a research note on Wednesday, October 7th. Weiss Ratings downgraded shares of Afya from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Finally, Wall Street Zen raised shares of Afya from a “hold” rating to a “buy” rating in a report on Saturday, September 5th.
Read Our Latest Stock Report on AFYA
Afya Price Performance
Shares of AFYA stock opened at $15.09 on Tuesday. The company has a quick ratio of 2.20, a current ratio of 2.20 and a debt-to-equity ratio of 0.39. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of 9.20, a PEG ratio of 1.83 and a beta of 0.34. The business’s fifty day moving average is $13.97 and its 200 day moving average is $14.24. Afya has a twelve month low of $11.62 and a twelve month high of $16.16.
Afya (NASDAQ:AFYA – Get Free Report) last posted its quarterly earnings results on Friday, August 14th. The company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.03. The firm had revenue of $187.80 million during the quarter, compared to analyst estimates of $189.62 million. Afya had a return on equity of 17.58% and a net margin of 20.55%. Research analysts expect that Afya will post 1.72 EPS for the current fiscal year.
Insider Transactions at Afya
In related news, insider Santos Welder Ferreira sold 4,161 shares of Afya stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $13.30, for a total transaction of $55,341.30. Following the completion of the transaction, the insider directly owned 35,000 shares in the company, valued at $465,500. The trade was a 10.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.80% of the company’s stock.
Institutional Investors Weigh In On Afya
An institutional investor recently bought a new position in Afya stock. Engineers Gate Manager LP purchased a new position in shares of Afya Limited (NASDAQ:AFYA – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 21,882 shares of the company’s stock, valued at approximately $325,000. Institutional investors own 88.02% of the company’s stock.
About Afya
Afya Limited is a medical education and digital health company focused on Brazil. Through its educational platform, the company provides undergraduate medical education, medical residency preparation, specialization and continuing medical education programs, and other learning resources for students and physicians.
Afya also offers digital products and services intended to support healthcare professionals throughout their careers. These include clinical content, study tools, telemedicine and practice-management solutions, and subscription-based applications designed to assist physicians with education, clinical decision-making, and patient care.
The company has expanded through the development and acquisition of medical schools, education businesses, and health technology platforms serving different stages of the medical professional lifecycle.
Recommended Stories
- Five stocks we like better than Afya
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Afya Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Afya and related companies with MarketBeat.com's FREE daily email newsletter.
